Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 15 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for a transdermal system used to prevent pregnancy. This approval marks the third hormonal transdermal patch from Zydus' generics portfolio. The product will be manufactured at the company's facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 15, 2023, titled "Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases